← All companies

BeOne

4 reports

Research on this company

Morgan Stanley

Morgan Stanley: BeOne Medicines’ third-quarter revenue beats expectations; solid-tumor pipeline models raised substantially

BeOne Medicines’ third-quarter revenue grew year over year, with global Brukinsa sales reaching 1.4 billion dollars; Morgan Stanley raised its long-term sales model for the solid-tumor pipeline, but the upward revision to 2026 GAAP EPS was driven mainly by a one-time tax item, and the company’s full-year revenue guidance was slightly below the firm’s forecast.